Cytosorbents (CTSO) Enterprise Value Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Enterprise Value Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.43 Bn | 193.83 Bn | 7.27 Bn |
| 2 | Stryker | 126.52 Bn | 123.04 Bn | 4.50 Bn |
| 3 | Medtronic | 118.76 Bn | 109.54 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.20 Bn | 47.95 Bn | 1.35 Bn |
| 6 | Dexcom | 34.51 Bn | 32.56 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.65 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.09 Bn | 22.61 Bn | 684.20 Mn |
| 10 | Cytosorbents | 19.58 Mn | 15.16 Mn | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.60% |
| Mar 31, 2026 | 36.84% |
| Dec 31, 2025 | 34.41% |
| Sep 30, 2025 | 30.61% |
| Jun 30, 2025 | 30.32% |
| Mar 31, 2025 | 32.71% |
| Dec 31, 2024 | 34.33% |
| Sep 30, 2024 | 52.60% |
| Jun 30, 2024 | 49.48% |
| Mar 31, 2024 | 49.90% |
| Dec 31, 2023 | 41.73% |
| Sep 30, 2023 | 54.37% |
| Jun 30, 2023 | 27.92% |
| Mar 31, 2023 | 10.30% |
| Dec 31, 2022 | -21.88% |
| Sep 30, 2022 | -12.17% |
| Jun 30, 2022 | -22.67% |
| Mar 31, 2022 | -29.86% |
| Dec 31, 2021 | -32.59% |
| Sep 30, 2021 | -34.82% |